NeoGenomics (NEO) Leerink Global Healthcare Conference 2026 summary

Key leadership insights and operational learnings

• Greater alignment between commercial and R&D teams has accelerated product development and innovation, with notable progress in the PanTracer and RaDaR portfolios over the past 12–18 months.

• Earlier investment in growth opportunities could have yielded faster product launches and market impact.

• Operational improvements have led to better turnaround times and efficiency, revealing untapped potential in the organization.

• Recent talent additions have brought fresh perspectives and contributed to a stronger, more innovative culture.

Financial philosophy and guidance

• Emphasis on high-confidence guidance, balancing growth with profitability, and prudent capital allocation, especially in G&A and automation.

• 2026 guidance assumes 9–10% growth, with mid-single-digit volume and AUP growth after adjusting for the exit of low-value contracts.

• Adjusted EBITDA margin is expected to expand by 100 basis points to 7% in 2026, with further margin expansion anticipated as new products mature in 2027–2028.

Revenue and pricing dynamics

• Exiting a high-volume, low-value contract and Pathline has led to sequential volume declines in Q4 and Q1, but sets up for sequential growth from Q2 onward.

• AUP growth is expected to accelerate as these contracts are phased out, with pricing increases and higher-value test mix driving multi-year tailwinds.

• NGS volumes, representing 9–10% of total volume and a third of revenue, are growing at 22–23% and are expected to remain strong.